Abstract Background Systemic sclerosis (SSc) is a rare connective tissue disease with a
heterogeneous clinical course. Interstitial lung disease (ILD) is a common manifestation of …

Two antifibrotic medications (nintedanib and pirfenidone) were recommended
(conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the …

Systemic sclerosis (SSc) has the highest cause-specific mortality of all the connective tissue
diseases, and the aetiology of this complex and heterogeneous condition remains an …

Systemic sclerosis (SSc) is a complex rheumatologic autoimmune disease in which
inflammation, fibrosis, and vasculopathy share several pathogenic pathways that lead to …

The specter of rapidly progressive lung disease requires clinicians to risk stratify patients
according to known predictors for progression and rigorously monitor for symptoms and …

Interstitial lung disease (ILD) refers to a large and heterogeneous group of parenchymal
lung disorders [1], some related to other diseases such as connective tissue diseases …

Introduction Rheumatoid arthritis (RA) is the most common of the connective tissue diseases
(CTD), affecting up to 0.75% of the United States (US) population with an increasing …

SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and
mortality. Evidence of interstitial lung disease (ILD) is seen in∼ 80% of patients with SSc …

Systemic sclerosis, also known as scleroderma (SSc), is a multisystem connective tissue
disease–associated with significant morbidity and mortality. It was first described in 1752 by …

Systemic sclerosis (SSc) is a progressive and often devastating disease characterized by
autoimmune dysfunction, vasculopathy, and fibrosis. Interstitial lung disease (ILD) is …